www.uhasselt.be
DSpace

Document Server@UHasselt >
Research >
Research publications >

Please use this identifier to cite or link to this item: http://hdl.handle.net/1942/2345

Title: T cell vaccination in multiple sclerosis patients with autologous CSF-derived activated T cells: results from a pilot study
Authors: VAN DER AA, Annegret
HELLINGS, Niels
MEDAER, Rob
Gelin, G
PALMERS, Yvan
RAUS, Jef
STINISSEN, Piet
Issue Date: 2003
Publisher: BLACKWELL PUBLISHING LTD
Citation: CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 131(1). p. 155-168
Abstract: Myelin-reactive T cells are considered to play an essential role in the pathogenesis of multiple sclerosis (MS), an autoimmune disease of the central nervous system. We have previously studied the effects of T cell vaccination (TCV), a procedure by which MS patients are immunized with attenuated autologous myelin basic protein (MBP)-reactive T cell clones. Because several myelin antigens are described as potential autoantigens for MS, T cell vaccines incorporating a broad panel of antimyelin reactivities may have therapeutic effects. Previous reports have shown an accumulation of activated T cells recognizing multiple myelin antigens in the cerebrospinal fluid (CSF) of MS patients. We conducted a pilot clinical trial of TCV with activated CD4(+) T cells derived from CSF in five MS patients (four RR, one CP) to study safety, feasibility and immune effects of TCV. CSF lymphocytes were cultured in the presence of rIL-2 and depleted for CD8 cells. After 5-8 weeks CSF T cell lines (TCL) were almost pure TCRalphabeta (+) CD4(+) cells of the Th1/Th0 type. The TCL showed reactivity to MBP, MOG and/or PLP as tested by Elispot and had a restricted clonality. Three immunizations with irradiated CSF vaccines (10 million cells) were administered with an interval of 2 months. The vaccinations were tolerated well and no toxicity or adverse effects were reported. The data from this small open-label study cannot be used to support efficacy. However, all patients remained clinically stable or had reduced EDSS with no relapses during or after the treatment. Proliferative responses against the CSF vaccine were observed in 3/5 patients. Anti-ergotypic responses were observed in all patients. Anti-MBP/PLP/MOG reactivities remained low or were reduced in all patients. Based on these encouraging results, we recently initiated a double-blind placebo-controlled trial with 60 MS patients to study the effects of TCV with CSF-derived vaccines in early RR MS patients.
Notes: Limburgs Univ Ctr, Biomed Onderzoeksinst BIOMED, B-3590 Diepenbeek, Belgium. Transnatl Univ, Sch Life Sci, Diepenbeek, Belgium. Zienkenhuis Oost Limburg, Dept Med Imaging, Genk, Belgium.Stinissen, P, Limburgs Univ Ctr, Biomed Onderzoeksinst BIOMED, Univ Campus Bldg A, B-3590 Diepenbeek, Belgium.
URI: http://hdl.handle.net/1942/2345
DOI: 10.1046/j.1365-2249.2003.02019.x
ISI #: 000180250500022
ISSN: 0009-9104
Category: A1
Type: Journal Contribution
Validation: ecoom, 2004
Appears in Collections: Research publications

Files in This Item:

There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.